International multicenter retrospective observational study consisting of two parts: a nested case-control study (part A) and a comparative retrospective cohort study (part B).
The study will include ET patients (diagnosed according to "International consensus classification of myeloid neoplasms and acute leukemias - 2022" criteria) who are JAK2V617F positive and have progressed to PV (diagnosed according to "International consensus classification of myeloid neoplasms and acute leukemias - 2022" criteria) by 31/12/2020. The date of PV diagnosis will be defined as the index date and this group of patients will be defined as ET-to-PV cases. Part A - Nested case-control study Controls for ET-to-PV cases will be patients diagnosed with ET, according to the "International consensus classification of myeloid neoplasms and acute leukemias - 2022" criteria, JAK2V617F positive who did not progress to PV after a comparable period of time. This control group will be selected using a 1:1 matched case-control design. For each patient who progressed to PV (case), a control will be selected with the following characteristics: * year of ET diagnosis (+/-2 years as compared to the date of the case); * age at ET diagnosis (+/-3 years as compared to the age of the case); * duration of ET disease (+/-2 years as compared to the period between the diagnosis of ET and the index date of the respective case). Part B - Comparative retrospective cohort study Patients diagnosed with de novo PV (no progression from previous ET) according to the "International consensus classification of myeloid neoplasms and acute leukemias - 2022" data criteria, will be recruited using a 1:1 matching procedure according to the following characteristics: * year of PV diagnosis (+/-2 years as compared to the date of the case); * age at PV diagnosis (+/-3 years as compared to the age of the case); * duration of PV disease (+/-2 years as compared to the period between PV diagnosis and the last follow-up of the respective case). Furthermore, to have at least 5 years of follow-up, de novo PV patients must be diagnosed no later than 2020.
Study Type
OBSERVATIONAL
Enrollment
678
Nested case-control study
To identify proliferative risk factors for progression from ET to PV in JAK2V617F positive patients.
Time frame: Up to the baseline
Comparative retrospective cohort study
To evaluate the different disease prognosis in ET patients who have progressed to PV compared to de novo PV patients.
Time frame: Up to the baseline
Nested case-control study
To describe characteristics of ET patients who progressed to PV, including the timing of progression.
Time frame: At the time of progression
Comparative retrospective cohort study
To compare the incidence of different outcomes (vascular events, progression to myelofibrosis, progression to acute myeloid leukaemia, tumours, death) in ET patients who progressed to PV and in de novo PV patients.
Time frame: At the time of progression
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Mayo Clinic
Rochester, Minnesota, United States
NOT_YET_RECRUITINGUniversity Hospital Halle
Halle, Germany
NOT_YET_RECRUITINGHannover Medical School
Hanover, Germany
NOT_YET_RECRUITINGUniversity Clinic for Hematology, Oncology, Hemostaseology and Palliative Care Johannes Wesling Medical Center
Minden, Germany
NOT_YET_RECRUITINGDivisione Ematologia, Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, Italy
NOT_YET_RECRUITINGDivisione Ematologia, Ospedale San Bortolo
Vicenza, Veneto, Italy
NOT_YET_RECRUITINGA.S.O. SS. Antonio e Biagio e C.Arrigo, SC Ematologia
Alessandria, Italy
NOT_YET_RECRUITINGASST Papa Giovanni XXIII, SC Ematologia
Bergamo, Italy
RECRUITINGASST-Spedali Civili
Brescia, Italy
NOT_YET_RECRUITINGOspedale Businco
Cagliari, Italy
NOT_YET_RECRUITING...and 15 more locations